Socazolimab Injection
The latest announcement on the official website of the China National Medical Products Administration (NMPA) shows that the Class 1 biological new drug #socazolimab# (formerly known as: Socazolimab) has been officially approved. According to public information, this is an anti-PD-L1 monoclonal antibody, and the approved indication this time is: treatment of recurrent or metastatic cervical cancer.
